Literature DB >> 182914

Persistent herpes simplex virus infections established in two Burkitt lymphoma derived cell lines.

W G Robey, B J Graham, C L Harris, M J Madden, G R Pearson, G F Vande Woude.   

Abstract

Examination of P3HR-I cells (Epstein-Barr virus [EBV] producer) persistently infected with the MAL strain of herpes simplex virus type I (HSV-I) suggested that only a few cells were actively producing a virus indistinguishable from HSV-I (MAL) despite the presence of immunofluorescent HSV-I antigens associated with the majority of cells. EBV-specific immunofluorescence was not altered in HSV-I persistently infected P3HR-I cells. HSV-I persistently infected cells, labelled for 72 h with 14C-thymidine, incorporated approx. 8% of the label into cell associated HSV-I DNA as resolved by caesium chloride gradients. Values greater than 8% of the total were suggested by hybridization of gradient fractions with 3H-HSV-I DNA. To determine whether the establishment of HSV persistent infections in Burkitt lymphoma derived cells was a general phenomenon, six strains of HSV-I (MAL, KOS, Patton, Syn R, BF and SYN V) and two strains of type 2 (333 and MS) were used to infect the P3HR-I and Raji (EBV non-producer) cell lines derived from Burkitt lymphomas. In P3HR-I cells, persistent infections were established with all strains of HSV-I but not with HSV-2. In Raji cells, persistent infections were established with all strains of HSV-I, except Syn V, and with both strains of HSV-2. No external support was required to maintain these infections.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 182914     DOI: 10.1099/0022-1317-32-1-51

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  16 in total

1.  Persistent infection of a human lymphoblastoid cell line with equine herpesvirus 1.

Authors:  L F Roumillat; P M Feorino; P D Lukert
Journal:  Infect Immun       Date:  1979-05       Impact factor: 3.441

2.  Persistent infection of human lymphoid and myeloid cell lines with herpes simplex virus.

Authors:  C R Rinaldo; B S Richter; P H Black; M S Hirsch
Journal:  Infect Immun       Date:  1979-08       Impact factor: 3.441

3.  Physical map of the origin of defective DNA in herpes simplex virus type 1 DNA.

Authors:  B J Graham; Z Bengali; G F Vande Woude
Journal:  J Virol       Date:  1978-03       Impact factor: 5.103

4.  Shared ancestry of herpes simplex virus 1 strain Patton with recent clinical isolates from Asia and with strain KOS63.

Authors:  Aldo Pourchet; Richard Copin; Matthew C Mulvey; Bo Shopsin; Ian Mohr; Angus C Wilson
Journal:  Virology       Date:  2017-12       Impact factor: 3.616

5.  Sequential detection of different antigens induced by Epstein-Barr virus and herpes simplex virus in the same Western blot by using dual antibody probes.

Authors:  J C Lin; J S Pagano
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

6.  Characterization of herpes simplex virus persistence in a human T lymphoblastoid cell line.

Authors:  P J Cummings; R J Lakomy; C R Rinaldo
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

7.  Analysis and characterization of herpes simplex virus after its persistence in a lymphoblastoid cell line for 15 months.

Authors:  L F Roumillat; P M Feorino; D D Caplan; P D Lukert
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

8.  Differential effects of acyclovir and 9-(1,3-dihydroxy-2-propoxymethyl)guanine on herpes simplex virus and Epstein-Barr virus in a dually infected human lymphoblastoid cell line.

Authors:  C M van der Horst; J C Lin; N Raab-Traub; M C Smith; J S Pagano
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

9.  Persistent infection with mouse hepatitis virus 3 in mouse lymphoid cell lines.

Authors:  L M Lamontagne; J M Dupuy
Journal:  Infect Immun       Date:  1984-06       Impact factor: 3.441

10.  Alpha interferon and acyclovir treatment of herpes simplex virus in lymphoid cell cultures.

Authors:  S M Hammer; J C Kaplan; B R Lowe; M S Hirsch
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.